3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
92
Breast Neoplasms
86
Neoplasms
79
Prostatic Neoplasms
50
Lung Neoplasms
44
Neoplasm Metastasis
40
Colorectal Neoplasms
37
Leukemia, Myeloid, Acute
32
Pain
27
Head and Neck Neoplasms
25
Colonic Neoplasms
25
Multiple Myeloma
24
Ovarian Neoplasms
23
Lymphoma
23
Carcinoma, Hepatocellular
23
Pancreatic Neoplasms
22
Lymphoma, Follicular
21
Melanoma
20
Leukemia
20
Rectal Neoplasms
19
Lymphoma, Non-Hodgkin
19
Urinary Bladder Neoplasms
17
Recurrence
17
Stomach Neoplasms
15
Lymphoma, Large B-Cell, Diffuse
15
Leukemia, Lymphocytic, Chronic, B-Cell
15
Squamous Cell Carcinoma of Head and Neck
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
13
Leiomyoma
13
Interventions
trifluridine tipiracil drug combination
1
regorafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Terminated
×
Spinocerebellar Degenerations
×
Clear all
NCT05328908
2025-08-13
RELATIVITY-123
Bristol-Myers Squibb
Phase 3
Terminated
770 enrolled